期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 52, 期 7, 页码 1803-1813出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm801072v
关键词
-
资金
- NIH [MH-65099, GM-70044, 1S10RR013005-01]
- Sanofi Research [SR48692]
- National Institute of Health [C06RR015455]
- National Center for Research Resources
Neurotensin(8-13) and two related analogues were used as model systems to directly compare various N-terminal peptide modifications representing both commonly used and novel capping groups. Each N-terminal modification prevented aminopeptidase cleavage but surprisingly differed in its ability to inhibit cleavage at other sites, a phenomenon attributed to long-range conformational effects. None of the capping groups were inherently detrimental to human neurotensin receptor 1 (hNTR1) binding affinity or receptor agonism. Although the most stable peptides exhibited the lowest binding affinities and were the least potent receptor agonists, they produced the largest in vivo effects. Of the parameters studied only stability significantly correlated with in vivo efficacy, demonstrating that a reduction in binding affinity at NTR1 can be countered by increased in vivo stability.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据